Information Provided By:
Fly News Breaks for October 22, 2019
PLAN
Oct 22, 2019 | 05:47 EDT
Evercore ISI analyst Stewart Materne upgraded Anaplan to Outperform from In Line with a $57 price target.
News For PLAN From the Last 2 Days
PLAN
Feb 27, 2020 | 17:41 EDT
Coronavirus fears continue to grip the market as cases in California, aggressive response measures in countries outside of the U. S... To see the rest of the story go to thefly.com. See Story Here
PLAN
Feb 27, 2020 | 13:08 EST
FBN Securities analyst Shebly Seyrafi lowered the firm's price target on Anaplan to $60 from $70 and keeps an Outperform rating on the shares. The analyst cites the Q4 billings miss and departure of the company's Chief Growth Officer for the target cut.
PLAN
Feb 27, 2020 | 12:19 EDT
Stocks are extending the pullback that has taken the S&P from a record high to a correction in a matter of only ten days as headlines about the coronavirus continue to dominate sentiment. In some the... To see the rest of the story go to thefly.com. See Story Here
PLAN
Feb 27, 2020 | 10:00 EST
Anaplan is down -22.0%, or -$12.76 to $45.33.
PLAN
Feb 27, 2020 | 09:13 EST
HIGHER: Gilead (GILD), up 7% after announcing the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19, or novel coronavirus... Sorrento Therapeutics (SRNE), up 1% after announcing it has initiated a clinical and manufacturing collaboration with Celularity to expand the therapeutic use of Celularity's CYNK-001, an allogeneic, off-the-shelf, placental-derived Natural Killer cell therapy, to the treatment and prevention of coronavirus infections. UP AFTER EARNINGS: Square (SQ), up 6%... Etsy (ETSY), up 9%. DOWN AFTER EARNINGS: AB InBev (BUD), down 9%... Discovery (DISCA), down 6%... QEP Resources (QEP), down 19%... Anaplan (PLAN), down 32%... Portola Pharmaceuticals (PTLA), down 15%. ALSO LOWER: Tesla (TSLA), down 6% after Bloomberg reported registrations of new Teslas in China plunged 46% last month as the coronavirus outbreak adds to a slump in the country's car market... Virgin Galactic (SPCE), down 16% after Morgan Stanley analyst Adam Jonas downgraded shares to Equal Weight from Overweight and Credit Suisse analyst Robert Spingarn also downgraded the stock to Neutral from Outperform.
PLAN
Feb 27, 2020 | 08:45 EST
After several quarters of billings growth in the 40s and 50s percentages, Anaplan reported 25% year-over-year billings growth in Q4, Barclays analyst Raimo Lenschow tells investors in a post-earnings research note. The stock in premarket trading is down 27%, or $15.48, to $42.61. The billings deceleration overshadowed an otherwise "healthy" Q4, adds the analyst. He believes that while difficult billings comparisons is certainly be a factor, the departure of the recently hired Chief Growth Officer "hints at deeper issues." Lenschow keeps an Equal Weight rating on Anaplan.